For US Healthcare Professionals Only
For US Healthcare Professionals Only
CLS Health and Baylor College of Medicine
Houston, TX
Senior Consultant
Nephrology Associates of Northern Illinois
Oak Brook, IL
Professor of Medicine, Anne Burnette School of Medicine
Fort Worth, TX
President, Desert Kidney Care Co-Director, Eisenhower Medical Center Graduate Medical Education in Nephrology
Rancho Mirage, CA
Assistant Professor of Medicine, Albany Medical College
Albany, NY
Partner at North Georgia Kidney Specialists
Atlanta, GA
Private Practice Nephrology
Nephrology and HTN Medical Associates
Savannah, GA
North Carolina Nephrology
Raleigh, NC
Balboa Nephrology Medical Group, Inc.
La Mesa, CA
Hypertension Nephrology Associates, PC
Livonia, MI
Assistant Professor of Medicine, Indiana University School of Medicine
Terre Haute, IN
Partner/Owner of Metro Renal Associates
Washington, DC
Ardelyx, Inc.
Waltham, MA
US Renal Care
Long Beach, CA
El Paso Kidney Specialists Clinical Associate Professor of Medicine, Division of Nephrology & Hypertension, Texas Tech University Health Sciences Center
El Paso, TX
Medical Director of Nephrology Services, Great Plains Health Nephrology
Medical Director of Outpatient Dialysis, Fresenius Medical Care
North Platte, NE
Nevada Kidney Disease & Hypertension Centers
Las Vegas, NV
Transplant Nephrologist, Southwest Kidney Institute
Tempe, AZ
Clinical Professor of Medicine, Morsani College of Medicine Lehigh Valley Hospital Network
Allentown, PA
Chief of Nephrology, Northwell Plainview
Medical Director, Davita Oyster Bay Dialysis
Albertson, NY
Physician Partner,
Florida Kidney Physicians
Boca Raton, FL
Medical Director,
Vibra Healthcare
Portland, OR
Central Florida Kidney Specialists
Orlando, FL
Health Sciences Clinic Professor, Director of Ambulatory Kidney Care Services, Outreach and Innovation, UC Davis School of Medicine
Sacramento, CA
Logan University
St. Louis, MO
Associate Clinical Professor of Medicine
David Geffen School of Medicine UCLA
Los Angeles, CA
Director & Nephrologist - Permian Basin Kidney Center Inc,
Clinical Professor (Internal Medicine) - Texas Tech University Health Sciences Center
Odessa, TX
SVP Nephrology
Ardelyx, Inc.
Professor of Medicine University of Chicago NorthShore-Endeavor Healthcare
Evanston, IL
South Texas Renal Care Group
San Antonio, TX
Senior Partner at Bergen Kidney Center
Englewood, NJ
XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
XPHOZAH is contraindicated in:
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.
For additional safety information, please see full Prescribing Information.
XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
XPHOZAH is contraindicated in:
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.
For additional safety information, please see full Prescribing Information.
